OABIW
OmniAb Inc.NASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.62
52W High
$0.30
52W Low
$0.08
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About OmniAb Inc.
OmniAb Inc. is a prominent biotechnology firm specializing in the discovery and development of fully human therapeutic antibodies via its proprietary OmniAb platform. This advanced platform enables the generation of highly diverse antibody libraries, placing OmniAb at the vanguard of drug development, especially within oncology and autoimmune disorders. With a strong pipeline and strategic collaborations, the company is well-positioned to leverage the growing demand for innovative antibody therapies, aligning with major trends in biotechnology and personalized medicine to improve patient outcomes and foster sustainable growth.
Fundamentals
| Revenue (TTM) | $18.67M |
| Gross Profit (TTM) | $18.36M |
| EBITDA | $-46.89M |
| Operating Margin | -147.40% |
| Return on Equity | -23.40% |
| Return on Assets | -13.00% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $1.85 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -22.50% |
| Shares Outstanding | 0 |
| Float | $97.34M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
178.75%
HV 20-Day
154.84%
HV 30-Day
136.63%
HV 60-Day
106.60%
HV Rank
—
Volatility is currently expanding
Data last updated: 5/5/2026